Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

Januvia and Remicade sales take a hit

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
 
4Q Revenues: $10.2 billion (-3%)

4Q Earnings: $976 million (earnings were $7.3 billion 4Q14)

FY Revenues: $39.5 billion (-6%)

FY Earnings: $4.4 billion (earnings were $11.9 billion FY14)

Comments: Revenues include a 7% negative impact from foreign exchange and 3% favorable impact from acquisitions and divestitures, primarily the acquisition of Cubist Pharmaceuticals. Januvia sales were down 12% to $1.4 billion likely due to a recent FDA safety alert about risk of joint pain, as well as the timing of purchases, according to the company. Sales of Remicade decreased 29% to $396 million due to loss of exclusivity and the impact of competition. Sales of Singulair, Zostavax, and Nasonex were all down 14% in the quarter. HPV vaccine Gardasil sales increased 40% to $497 million due to increased government purchases in the U.S. Keytruda performed well in the quarter with sales of $214 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters